Presenilin 1 Glu318Gly Polymorphism: Interpret With Caution | Genetics and Genomics | JAMA Neurology | JAMA Network
[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
October 2005

Presenilin 1 Glu318Gly Polymorphism: Interpret With Caution

Author Affiliations

Author Affiliations: Department of Neurology, Memory and Aging Center, University of California, San Francisco (Ms Goldman and Drs Johnson and Miller); Department of Medical Genetics, Alberta Children’s Hospital, Calgary, Alberta (Ms McElligott); Department of Clinical Neurosciences, University of Calgary, Calgary (Dr Suchowersky); and Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, University of Pennsylvania Medical Center, Philadelphia (Dr Van Deerlin).

Arch Neurol. 2005;62(10):1624-1627. doi:10.1001/archneur.62.10.1624

Background  The significance of the presenilin 1 (PSEN1) Glu318Gly polymorphism has been described as either a causal mutation with reduced penetrance or a benign polymorphism. When this polymorphism is found in a symptomatic person with a family history of dementia, counseling on recurrence risk becomes very problematic.

Objective  To demonstrate that the PSEN1 Glu318Gly polymorphism should be interpreted cautiously.

Design  Case histories of 2 patients with presenile dementia and family histories of dementia are described. The PSEN1 gene was sequenced in the patients and in 11 family members of patient 1.

Results  Two patients with presenile dementia and personality change were found to carry the PSEN1 Glu318Gly polymorphism. The presence of the polymorphism was confirmed in several family members of patient 1 but was absent in 1 symptomatic relative.

Conclusions  The Glu318Gly polymorphism may be associated with risk for neurodegenerative disease; however, in the cases described here, it did not appear to be a risk factor. Until there is consensus on whether it is associated with disease, families should be informed that the clinical significance of the polymorphism is uncertain.